Equities analysts expect Dynavax Technologies Co. (NASDAQ:DVAX) to report earnings per share of ($0.58) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Dynavax Technologies’ earnings. The highest EPS estimate is ($0.56) and the lowest is ($0.60). Dynavax Technologies posted earnings of ($0.38) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 52.6%. The business is scheduled to report its next quarterly earnings report on Friday, November 2nd.

On average, analysts expect that Dynavax Technologies will report full-year earnings of ($2.39) per share for the current financial year, with EPS estimates ranging from ($2.42) to ($2.33). For the next year, analysts anticipate that the business will report earnings of ($1.46) per share, with EPS estimates ranging from ($1.70) to ($1.23). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that cover Dynavax Technologies.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.01). Dynavax Technologies had a negative net margin of 8,570.06% and a negative return on equity of 72.31%. The business had revenue of $1.25 million during the quarter, compared to analyst estimates of $1.88 million. During the same period in the previous year, the company earned ($0.41) earnings per share. The business’s revenue for the quarter was up 1094.3% on a year-over-year basis.

A number of brokerages have issued reports on DVAX. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $30.00 target price on shares of Dynavax Technologies in a research report on Monday, August 6th. ValuEngine lowered Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Tuesday, May 1st. BidaskClub lowered Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Friday, June 8th. Finally, JPMorgan Chase & Co. raised Dynavax Technologies from a “neutral” rating to an “overweight” rating and set a $25.00 target price on the stock in a research report on Thursday, May 10th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. Dynavax Technologies presently has an average rating of “Hold” and a consensus price target of $27.50.

In other news, insider Michael S. Ostrach sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, June 8th. The stock was sold at an average price of $15.53, for a total value of $62,120.00. Following the completion of the sale, the insider now directly owns 80,554 shares in the company, valued at approximately $1,251,003.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 3.47% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN increased its holdings in shares of Dynavax Technologies by 9.2% in the 1st quarter. Wells Fargo & Company MN now owns 45,516 shares of the biopharmaceutical company’s stock valued at $903,000 after acquiring an additional 3,834 shares during the last quarter. Swiss National Bank increased its holdings in shares of Dynavax Technologies by 4.3% in the 1st quarter. Swiss National Bank now owns 104,178 shares of the biopharmaceutical company’s stock valued at $2,068,000 after acquiring an additional 4,300 shares during the last quarter. Creative Planning increased its holdings in shares of Dynavax Technologies by 2.6% in the 2nd quarter. Creative Planning now owns 235,105 shares of the biopharmaceutical company’s stock valued at $3,585,000 after acquiring an additional 5,857 shares during the last quarter. New York State Common Retirement Fund increased its holdings in shares of Dynavax Technologies by 10.8% in the 1st quarter. New York State Common Retirement Fund now owns 65,700 shares of the biopharmaceutical company’s stock valued at $1,304,000 after acquiring an additional 6,400 shares during the last quarter. Finally, Guggenheim Capital LLC increased its holdings in shares of Dynavax Technologies by 7.2% in the 1st quarter. Guggenheim Capital LLC now owns 112,278 shares of the biopharmaceutical company’s stock valued at $2,228,000 after acquiring an additional 7,522 shares during the last quarter. Institutional investors and hedge funds own 78.57% of the company’s stock.

Shares of DVAX traded up $0.02 during trading on Friday, reaching $12.60. The company’s stock had a trading volume of 511,000 shares, compared to its average volume of 1,449,532. Dynavax Technologies has a twelve month low of $12.25 and a twelve month high of $24.45. The firm has a market cap of $832.79 million, a price-to-earnings ratio of -7.28 and a beta of 0.29. The company has a quick ratio of 8.67, a current ratio of 8.87 and a debt-to-equity ratio of 0.76.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

Featured Story: Dividend

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.